广东凯普生物科技股份有限公司 2018 年第一季度报告全文 广东凯普生物科技股份有限公司 2018 年第一季度报告 2018 年 04 月 1 广东凯普生物科技股份有限公司 2018 年第一季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人黄伟雄、主管会计工作负责人李庆辉及会计机构负责人(会计主 管人员)罗翠红声明：保证季度报告中财务报表的真实、准确、完整。 2 广东凯普生物科技股份有限公司 2018 年第一季度报告全文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期 | 上年同期 | 本报告期比上年同期增减 | | --- | --- | --- | --- | | 营业总收入（元） | 106,936,394.21 | 86,891,154.00 | 23.07% | | 归属于上市公司股东的净利润（元） | 12,301,546.48 | ...

Financial Performance - The company's operating revenue for 2017 was CNY 479,085,119.83, representing a 20.28% increase compared to CNY 398,303,899.32 in 2016[17]. - The net profit attributable to shareholders for 2017 was CNY 93,210,017.92, which is a 22.49% increase from CNY 76,094,578.58 in the previous year[17]. - The net profit after deducting non-recurring gains and losses was CNY 83,312,524.79, up 15.68% from CNY 72,017,598.17 in 2016[17]. - The net cash flow from operating activities increased by 24.41% to CNY 79,165,085.97 from CNY 63,630,748.26 in 2016[17]. - The total assets at the end of 2017 reached CNY 1,069,642,003.50, an increase of 84.69% from CNY 579,151,551.19 at the end of 2016[17]. - The net assets attributable to shareholders increased by 96.25% to CNY 960,600,384.89 from CNY 489,489,313.01 in 2016[17]. - The basic earnings per share remained at CNY 1.13, unchanged from the previous year[17]. - The weighted average return on equity decreased to 11.83% from 16.88% in 2016, a decline of 5.05%[17]. Market Expansion and Product Development - The company is focused on expanding its market presence and enhancing its product offerings through ongoing research and development initiatives[4]. - The company is a leading provider of nucleic acid molecular diagnostic products, focusing on the R&D, production, and sales of related products[25]. - The product portfolio includes 13 types of high-risk HPV nucleic acid testing kits, which are used for detecting HPV infections, contributing to the company's revenue growth[26]. - The company has developed a range of diagnostic kits for infectious diseases and genetic disorders, enhancing its market position in the healthcare sector[27]. - The company plans to continue expanding its product offerings and market reach, leveraging its proprietary technology platforms[25]. - Revenue from HPV testing products and thalassemia testing products showed stable growth, while other reagent kits (STD, deafness susceptibility gene testing, etc.) grew by 31.60% compared to the previous year[29]. - The company has developed a comprehensive third-party medical testing service network across the country, which is expected to become another growth point for business revenue[29]. Research and Development - R&D investment for 2017 was ¥37,817,048.77, accounting for 7.89% of total revenue, slightly down from 8.00% in 2016[68]. - The number of R&D personnel remained stable at 218, representing 21.54% of the total workforce[68]. - The company is actively expanding its product portfolio with new genetic testing kits for thalassemia and hepatitis B virus detection[70]. - The company aims to enhance its diagnostic capabilities through the introduction of combined detection kits for multiple pathogens[70]. - The company is focusing on the development of advanced PCR and hybridization methods for more accurate and efficient testing[70]. Financial Management and Fundraising - The company successfully completed a fundraising of RMB 21,498.01 million for projects including nucleic acid diagnostic reagent expansion and medical testing center construction[46]. - The company has accumulated CNY 860 million in wealth management products by the end of 2017, indicating a strategic approach to managing idle funds[78]. - The total amount of funds raised in 2017 was RMB 372.25 million after deducting issuance costs of RMB 41.52 million[83]. - The company plans to use up to RMB 150 million of idle raised funds for cash management, including purchasing principal-protected financial products[85]. - The company is committed to transparency and compliance in its financial reporting[155]. Shareholder and Dividend Policies - The company plans to distribute a cash dividend of CNY 5.00 per 10 shares, totaling CNY 45,508,500.00 based on 91,017,000 shares[4]. - The company has a cash dividend policy that aligns with its articles of association and shareholder return plan, ensuring transparency and compliance[111]. - The company committed to maintaining a cash dividend policy, ensuring that cash dividends account for no less than 10% of the distributable profits for the year[117]. - The company plans to distribute cash dividends cumulatively over the last three years, amounting to at least 30% of the average distributable profits during that period[117]. Regulatory Compliance and Risk Management - The company reported no significant discrepancies between financial data disclosed under international and Chinese accounting standards[20][21]. - The company emphasizes the importance of risk management in technology innovation and product development to maintain its competitive edge[104]. - The company has established commitments to avoid competition with its controlling shareholders and related parties to ensure independent operations[118]. - The company has a quality management system in place to ensure product quality throughout the design, development, production, and sales processes[104]. Strategic Outlook - The company provided a future outlook, projecting a revenue growth of 25% for the next fiscal year, driven by new product launches and market expansion[124]. - The company plans to expand its market presence in Southeast Asia, targeting a 10% market share within the next three years[123]. - The company aims to improve operational efficiency by 15% through the implementation of new technologies in production processes[122]. - The company is exploring potential mergers and acquisitions to strengthen its market position and diversify its portfolio[158].

Financial Performance - Operating revenue for the period was CNY 125,580,286.46, reflecting a year-on-year growth of 23.50%[7] - Net profit attributable to shareholders rose by 43.72% to CNY 27,602,795.58[7] - Basic earnings per share increased by 7.80% to CNY 0.3067[7] - Total operating revenue for the current period reached ¥125,580,286.46, an increase of 23.5% compared to ¥101,680,664.14 in the previous period[36] - Total operating costs amounted to ¥96,988,140.38, up from ¥79,820,931.99, reflecting a growth of 21.5%[36] - Operating profit for the current period was ¥33,220,755.64, representing a 52.2% increase from ¥21,859,732.15 in the previous period[37] - Net profit attributable to shareholders was ¥27,602,795.58, a rise of 43.8% compared to ¥19,205,663.20 in the previous period[38] - Total comprehensive income for the current period was ¥27,855,595.96, compared to ¥18,609,461.18 in the previous period, indicating a growth of 49.5%[38] Assets and Liabilities - Total assets reached CNY 1,024,568,863.10, an increase of 76.91% compared to the previous year[7] - Total current assets increased significantly from CNY 248,908,784.78 to CNY 665,664,276.53, representing a growth of approximately 167%[28] - Total non-current assets grew from CNY 330,242,766.41 to CNY 358,904,586.57, an increase of about 8.5%[29] - Total liabilities increased from CNY 77,486,547.07 to CNY 85,788,822.44, which is an increase of about 10%[30] - The company’s total liabilities and equity reached CNY 1,024,568,863.10, up from CNY 579,151,551.19, indicating a total growth of about 77%[31] Shareholder Information - The total number of shareholders at the end of the reporting period was 12,182[11] - The largest shareholder, Hong Kong Science and Technology Venture Capital Co., Ltd., held 32.33% of the shares[11] - The equity attributable to the parent company rose from CNY 489,489,313.01 to CNY 929,216,167.08, representing an increase of approximately 90%[31] Cash Flow - The company reported a net cash flow from operating activities of CNY 37,575,937.09, up 70.70% year-to-date[7] - Cash flow from operating activities generated a net amount of CNY 37,575,937.09, significantly higher than CNY 22,013,230.59 in the same period last year, representing an increase of approximately 70.9%[52] - The net cash flow from financing activities was 387,072,828.03 CNY, significantly higher than 9,289,458.35 CNY in the previous period[55] - The total cash and cash equivalents at the end of the period reached 96,428,626.97 CNY, compared to 16,102,793.23 CNY at the end of the previous period[55] Operational Developments - The company implemented a restricted stock incentive plan, granting a total of 1,017,000 shares to 213 incentive objects[19] - The company successfully won bids for HPV testing in Zhejiang Province, becoming the only manufacturer to win in both categories of the tender[19] - The company approved the establishment of two wholly-owned subsidiaries, Guangzhou Kaijian Precision Medical Technology Service Co., Ltd. and Guangzhou Tiancheng Medical Equipment Co., Ltd.[20] Other Income and Expenses - Non-recurring gains and losses totaled CNY 3,814,175.21 for the year-to-date period[8] - Other income increased by 100% compared to the previous period, attributed to government subsidies related to daily operations[17] - Sales expenses rose to ¥47,915,048.06 from ¥39,777,696.80, an increase of 20.4%[37] - Management expenses increased to ¥27,553,229.07 from ¥22,133,668.18, reflecting a growth of 24.4%[37]

Financial Performance - The company reported a total revenue of RMB 9 million for the first half of 2017, representing a year-on-year increase of 15% compared to the same period in 2016[10]. - The net profit attributable to shareholders for the first half of 2017 was RMB 1.5 million, an increase of 20% year-on-year[10]. - Total revenue for the reporting period reached ¥210,310,198.55, an increase of 18.16% compared to ¥177,983,390.67 in the same period last year[20]. - Net profit attributable to shareholders was ¥37,576,993.09, reflecting a growth of 12.30% from ¥33,459,774.19 year-on-year[20]. - The company achieved a revenue of 210.31 million yuan in the first half of 2017, representing an 18.16% increase compared to the same period last year[49]. - Net profit attributable to shareholders reached 37.58 million yuan, marking a 12.30% year-on-year growth[49]. - The company reported a significant increase in revenue, achieving a total of 500 million RMB for the first half of 2017, representing a 25% year-over-year growth[108]. - Earnings per share (EPS) for the first half of 2017 was ¥0.501, slightly up from ¥0.496 in the previous year[178]. Share Capital and Dividends - The total share capital increased from 67.5 million shares to 90 million shares following the public offering of 22.5 million shares in April 2017[17]. - The company will not distribute cash dividends or issue bonus shares for the reporting period[5]. - The company’s registered capital increased to RMB 90 million as part of its growth strategy[18]. - The company has committed to a stable profit distribution policy, with cash dividends accounting for at least 10% of the distributable profits each year[101]. - The company plans to maintain a cash dividend ratio of no less than 30% of the average annual distributable profits over the last three years[101]. - The company will not distribute cash dividends if the asset-liability ratio exceeds 75% at year-end[102]. Research and Development - The company is focusing on the research and development of in vitro diagnostic reagents and instruments, aiming to improve its technological capabilities[18]. - The company has received two US patents for its proprietary nucleic acid hybridization technology, which enhances the speed and sensitivity of diagnostic tests[9]. - The company plans to enhance its research and development investment in molecular diagnostic reagents to develop more high-quality products[31]. - The company has over 30 products in the research phase, with several products in the final clinical trial and registration application stages[37]. - The company is focusing on long-term strategies for product development, particularly in the areas of genetic testing and clinical diagnostics[65]. - The company aims to leverage its technological advancements to capture a larger share of the growing market for molecular diagnostics[65]. Market Expansion and Strategy - The company plans to expand its product line to include new high-tech biological detection instruments and reagents, enhancing its market presence[18]. - The company is expanding its business model to integrate "instruments + reagents + services" through the establishment of molecular medicine testing services[30]. - The company plans to establish approximately 25 "Kepu Testing Centers" across major provinces and cities in China, enhancing its integrated service model of "instruments + reagents + services"[44]. - The company is actively pursuing regulatory approvals for additional products to broaden its market reach[63]. - The company is expanding its market presence in Southeast Asia, targeting a 15% market share by 2019[108]. Financial Management and Investments - The company raised a total of 413,775,000.00 from the public offering, with net proceeds of 372,250,884.84 after deducting issuance costs[71]. - The company has invested 18,495.62 in the projects funded by the raised capital during the reporting period, with a cumulative investment of the same amount[71]. - The company reported a significant increase in cash flow from financing activities, reaching CNY 404,113,328.36, significantly up from CNY 16,050,000.00 in the previous period[185]. - The total cash outflow for investment activities was CNY 314,623,778.80, significantly higher than CNY 43,298,029.55 in the previous period, indicating aggressive investment strategies[188]. - The company has allocated RMB 15,000 million of idle funds for cash management, which includes purchasing principal-protected financial products or making fixed-term deposits[74]. Risk Management - The company emphasizes the importance of risk awareness among investors regarding forward-looking statements made in the report[4]. - The company faces risks related to industry policies and regulations, which could impact its operations if compliance issues arise[86]. - Market competition remains a concern, as the company must enhance its competitive advantages to avoid being at a disadvantage compared to larger international firms[86]. - The company emphasizes the importance of risk management in its R&D processes to mitigate potential failures in technology innovation[87]. Corporate Governance - The company has committed to protecting the interests of shareholders and investors by ensuring that no unfair benefits are provided to other entities or individuals[110]. - The company is currently in compliance with all commitments made during its IPO process, ensuring adherence to regulatory requirements[97]. - The company has established regulations to avoid potential competition with its controlling shareholders, ensuring operational independence[102]. - The company has implemented a series of governance measures to ensure fairness in related party transactions[103]. Product Development and Innovation - The company has developed numerous nucleic acid molecular diagnostic products, holding 44 domestic product registration certificates and 18 EU CE certified products[37]. - The company has launched a fully automated nucleic acid extraction instrument, improving efficiency in molecular testing[62]. - The company has obtained CE certification for multiple diagnostic kits, enhancing its market credibility and potential for expansion in Europe[66]. - The introduction of new products, including various nucleic acid extraction kits, is aimed at expanding applications in fields such as genomics, disease control, and forensic science[65]. Legal and Compliance - There were no major litigation or arbitration matters during the reporting period, indicating a stable legal environment for the company[113]. - The company has not faced any penalties or rectification issues during the reporting period, reflecting compliance with regulations[115]. - The half-year financial report for the company has not been audited, which may affect the reliability of the financial data presented[111].

广东凯普生物科技股份有限公司 2017 年第一季度报告全文 广东凯普生物科技股份有限公司 2017 年第一季度报告 2017 年 04 月 所有董事均已出席了审议本次季报的董事会会议。 公司负责人黄伟雄、主管会计工作负责人李庆辉及会计机构负责人(会计主 管人员)罗翠红声明：保证季度报告中财务报表的真实、准确、完整。 2 广东凯普生物科技股份有限公司 2017 年第一季度报告全文 第二节 公司基本情况 一、主要会计数据和财务指标 1 广东凯普生物科技股份有限公司 2017 年第一季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 公司是否因会计政策变更及会计差错更正等追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期 | 上年同期 | 本报告期比上年同期增减 | | --- | --- | --- | --- | | 营业总收入（元） | 86,891,154.00 | 74,243,254.12 | 17.04% | | 归属于上市公司股东的净利润（元） | 9, ...